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Abstract: Alternative splicing is a well-studied gene regulatory mechanism that produces biological
diversity by allowing the production of multiple protein isoforms from a single gene. An involvement
of alternative splicing in the key biological signalling Hippo pathway is emerging and offers new
therapeutic avenues. This review discusses examples of alternative splicing in the Hippo pathway,
how deregulation of these processes may contribute to disease and whether these processes offer new
potential therapeutic targets.
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1. Introduction
The Hippo pathway is a newly established serine-threonine kinase cell signalling pathway
implicated in several key developmental and homeostatic processes. Deregulation of the Hippo
pathway is thus associated with a suite of disease states including a variety of cancers such as breast,
pancreatic, prostate, liver, lung, bladder, gliomas, melanomas, sarcomas, colorectal, ovarian, gastric
and head and neck cancers (reviewed in [1]). As such, this emerging pathway and its components
have garnered considerable interest in recent years as a potential therapeutic target. Many of the
core proteins constituting the pathway are now well established and some of its earliest identified
biological roles include the control of cell proliferation and growth; however, the full repertoire of key
components, interactions and functions of the Hippo pathway are still being discovered. In particular,
a role for alternative splicing as a means for regulating the Hippo pathway is emerging and remains
to be fully understood. This review will briefly introduce the mechanism of alternative splicing and
summarises what is known about the functioning of the Hippo pathway, before moving on to examine
emerging evidence for a role for alternative splicing in the functioning and regulation of the Hippo
pathway. We will then explore the notion that aberrant alternative splicing of components involved in
the Hippo pathway could contribute to disease states and ask whether or not alternative splicing in
the Hippo pathway provides novel therapeutic targets.
2. Alternative Splicing and Disease
Alternative splicing (AS) was discovered over 35 years ago and is an important regulator of
multicellular eukaryotic gene function that allows for the production of multiple mature mRNAs
from a pre-mRNA. This means that a single gene can encode multiple protein isoforms with often
opposing functions. It is estimated that 95% of human genes are alternatively spliced [2], highlighting
the importance of AS in the regulation of gene expression. AS is a co-transcriptional process involving
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the differential inclusion or exclusion of particular exons of a gene in the final mature mRNA molecule.
AS patterns differ in specific tissues [3]; for example, the central nervous system in particular relies
heavily on AS to produce proteins required for its proper functioning. There are several principal
types of AS of human genes (summarised in Figure 1); these include skipping or retention of cassette
exons, the use of mutually exclusive exons, the use of an alternative 5′ donor splice site, the use of an
alternative 3′ acceptor splice site, intron retention, recursive splicing [4] and non-sequential splicing [5].
Genes 2018, 9, x FOR PEER REVIEW  2 of 19 
 
opposing functions. It is estimated that 95% of human genes are alternatively spliced [2], 
highlighting the importance of AS in the regulation of gene expression. AS is a co-transcriptional 
process involving the differential inclusion or exclusion of particular exons of a gene in the final 
mature mRNA molecule. AS patterns differ in specific tissues [3]; for example, the central nervous 
system in particular relies heavily on AS to produce proteins required for its proper functioning. 
There are several principal types of AS of human genes (summarised in Figure 1); these include 
skipping or retention of cassette exons, the use of mutually exclusive exons, the use of an 
alternative 5′ donor splice site, the use of an alternative 3′ acceptor splice site, intron retention, 
recursive splicing [4] and non-sequential splicing [5]. 
 
Figure 1. Principal types of alternative splicing of human genes. Pre-mRNA is shown on the left, 
and the mature product of the splicing process is shown on the right. Black and red lines indicate 
differential splicing outcomes. 
AS processes are highly conserved between taxa but the extent of AS differs across organisms 
and is more prominent in multicellular organisms [6]. Whereas in humans 95% of genes are 
alternatively spliced [2], recent reports suggest that there are only a few examples of functional AS 
in the budding yeast Saccharomyces cerevisiae [7,8] and that only two to three percent of genes in the 
fission yeast Schizosaccharomyces pombe are alternatively spliced [9,10]. In contrast, in Drosophila 
melanogaster 60% of genes are alternatively spliced [11]. AS is involved in regulating a variety of 
biological processes including cell division and apoptosis [12], differentiation during development 
and in adult tissues [3] as well as how cells respond to external stimuli (e.g., [13]). It is therefore 
not surprising that AS has been implicated in regulating key signalling pathways such as Ras-
MAPK and PI3K-mTOR signalling [14]. Aberrant AS is a major contributor to several neurological 
diseases including Duchenne muscular dystrophy (DMD) [15], spinal muscular atrophy (SMA) [16], 
diabetes [17] and is implicated in the development and progression of many types of cancer [18,19]. 
As such, there has been a lot of interest in using splice isoforms as disease biomarkers and in 
developing novel therapeutic strategies aimed at oncogenic splice isoforms [20,21]. 
Figure 1. Principal types of alternative splicing of human genes. Pre-mRNA is shown on the left,
and the mature product of the splicing process is shown on the right. Black and red lines indicate
differential splicing outcomes.
AS processes are highly conserved between taxa but the extent of AS differs across organisms and
is more prominent in multicellular organisms [6]. Whereas in humans 95% of genes are alternatively
spliced [2], recent reports suggest that there are only a few examples of functional AS in the budding
yeast Saccharomyces cerevisiae [7,8] and that only two to three percent of genes in the fission yeast
Schizosaccharomyces pombe are alternatively spliced [9,10]. In contrast, in Drosophila melanogaster 60%
of genes are alternatively spliced [11]. AS is involved in regulating a variety of biological processes
including cell division and apoptosis [12], differentiation during development and in adult tissues [3]
as well as how cells respond to external stimuli (e.g., [13]). It is therefore not surprising that AS has been
implicated in regulating key signalling pathways such as Ras-MAPK and PI3K-mTOR signalling [14].
Aberrant AS is a major contributor to several neurological diseases including Duchenne muscular
dystrophy (DMD) [15], spinal muscular atrophy (SMA) [16], diabetes [17] and is implicated in the
development and progression of many types of cancer [18,19]. As such, there has been a lot of interest
in using splice isoforms as disease biomarkers and in developing novel therapeutic strategies aimed at
oncogenic splice isoforms [20,21].
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3. Introduction to the Hippo Pathway
The Hippo pathway is a recently discovered cell signalling pathway implicated in key biological
processes. Despite only just over 20 years of research, the Hippo pathway has become established
as the main essential regulator of organ size, but new functions for this important pathway and its
components are still being elucidated. Whilst many of the core genes involved in the Hippo pathway
were discovered in Drosophila due to the overgrowth phenotypes generated by their mutation [22–26],
the pathway is highly conserved in mammals via orthologous genes. In mammals the pathway consists
of a core cassette of upstream serine-threonine kinases and adaptor proteins that serve to negatively
regulate the downstream effectors of the pathway (see Figure 2 for an overview), yes-associated
protein (YAP) and its paralogue, transcriptional co-activator with PDZ-binding motif (TAZ). YAP and
TAZ act as transcriptional co-activators to elicit expression of target genes regulated by the Hippo
pathway [27]. The activation of upstream Hippo components leads to the subsequent phosphorylation
of YAP/TAZ and their cytoplasmic sequestration blocking their activation of target genes in the
nucleus [27]. YAP/TAZ nuclear activity is achieved through binding with several transcription factors,
most prominently TEA Domain transcription factors (TEADs), but other examples include RUNX
transcription factors [28], SMAD proteins [29,30], FoxO [31] and p73 [32].
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Figure 2. An overview of the mammalian Hippo pathway. Hippo pathway members shown inside the
red dashed box are considered the core components of the Hippo pathway. Members with an asterisk
are those known to have alternative splicing variants. Dashed arrows indicate unknown mechanisms.
As such, the Hippo pathway interacts with a host of other signalling networks, including the
WNT pathway [33,34], Ras signalling [35], metabolic pathways [36–39] and pluripotency/stemness
pathways [40]. Due to this cross-talk, there are many regulatory inputs into the Hippo pathway
including those that regulate cell polarity and adhesion [30,41], cell-cell contact [41,42], mechanical cues
such as extracellular matrix (ECM) stiffness and cell geometry [43,44] soluble factors such as hormones
and growth factors through G-protein-coupled receptors (GPCRs) [45–47], chemical stresses [48]
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as well as metabolic changes [49]. Consequently, to date the Hippo pathway has been implicated
in a diverse array of biological processes, the coordination of which is essential in multicellular
organisms for regulation of organ size. These processes include cell proliferation [50], apoptosis [51–53],
epithelial-to-mesenchymal-transition (EMT) [54] and cell migration [55,56], cellular plasticity [57],
stem cell biology [58], coordinated morphogenesis of tissues and development of three-dimensional
body shape [59] and regeneration [60]. In the liver, over-activation of YAP for four to five weeks was
shown to increase organ size four to fivefold [61,62], and over-expression in the pancreas also caused
an enlargement [61]. Furthermore, YAP over-activation has been shown to cause epidermis thickening
and dysplasia of the intestinal epithelium [61]. The requirement of YAP in vivo is underscored by the
fact that homozygous deletion of YAP causes developmental arrest in mice by stage E8.5 accompanied
by defects in yolk sac vasculogenesis, a notably shortened body axis and a convoluted anterior
neuroepithelium [63].
4. Examples of Alternative Splicing in the Hippo Pathway
Recent work has shed light on the evolution of the Hippo pathway, suggesting that the manner
in which Hippo pathway genes have developed allows for species-specific control of growth [64].
For example, most of the Hippo pathway genes can be found in even the simplest metazoans despite
their basic body plans but Hippo genes exhibit more exons in advanced organisms where tissues are
multicellular and more complex in nature [64]. A study by Zhu et al. [64] found that although the
exon number of Hippo genes varied between species, functional domains were often highly conserved,
suggesting that Hippo pathway genes may be able to produce multiple protein isoforms by AS to allow
growth control across a variety of different tissues. Indeed, it appears that the functional domains
of Hippo pathway components have co-evolved with their interacting partners’ functional domains,
undergoing purifying selections (i.e., selective removal of domains that do not allow the protein
to achieve its function), highlighting the evolutionary importance of the pathway [64]. This study
concluded that AS might be the most important feature of Hippo pathway genes to produce multiple
proteins for tissue-specific growth control [64].
Whilst there is still much to learn regarding a role for AS in the Hippo pathway, there are several
lines of evidence suggesting AS is involved in regulating Hippo signalling. It remains to be seen
whether or not AS plays a more prominent role in regulating Hippo signalling versus other key
signalling pathways, but it is conceivable that AS could provide a more stable type of regulatory
mechanism versus the fast regulation afforded by the traditionally well-studied phosphorylation
cascade of the Hippo pathway [65]. The majority of the core components of the Hippo pathway are
known to have alternatively spliced isoforms (Table 1). The mammalian Ste20-like kinase-1 (MST1),
a serine/threonine kinase with a SARAH domain has 21 splice variants, with only two being protein
coding. The C-terminal truncated version of MST1 consists only of the kinase domain, whereas the
full-length MST1 isoform consists of the C-terminal regulatory region as well as the homodimerisation
SARAH domain [66]. SAV1 (a protein containing two WW domains, a SARAH domain, and a
coiled-coil region [67]) has six splice variants, with five of them producing proteins and MAP4K
(belonging to the mammalian Ste20-like family of serine/threonine kinases) has 15 transcripts with
five of them producing proteins and one undergoing nonsense-mediated decay (NMD). The kinase
co-activator MOB1 [68], also has six splice variants with just one transcript producing a 216-amino
acid protein. Finally, large tumour suppressor kinase 1 (LATS1), a serine/threonine kinase has seven
transcripts with four being protein encoding and two resulting in NMD whilst large tumour suppressor
kinase 2 (LATS2), also a serine/threonine kinase has two splice variants, one being protein coding.
YAP is comprised of nine exons and can undergo AS, and to date there are at least eight described
splice isoforms of the YAP gene expressed in human tissues [69]. These different YAP isoforms can
have different functions in different tissues as each version varies in transcriptional potency [70].
Furthermore, the different YAP isoforms can interact with different binding partners in different
contexts. For example, exon 4 skipping within YAP results in a protein with only one WW protein
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binding domain as opposed to the more frequent product that contains two WW domains [71,72].
WW domains are commonly occurring protein-protein interaction modules that recognise proline-rich
motifs [73] and the WW domains of YAP are crucial for the interaction of YAP with LATS protein
kinases [74]. There are several functional consequences of YAP having only one WW domain, one being
that YAP can no longer bind angiomotin, a member of the tight junction complex, which is normally
involved in sequestering YAP in the cytoplasm [75]. Additionally, YAP can also no longer bind p73
without the second WW domain, meaning it can no longer exert its pro-apoptotic functions under
conditions of physiological stress [76]. YAP exon 5 has an alternative splice donor site producing a
longer transcript (exon 5B), and together with cassette exon 6, can vary the transcriptional activation
domain (TAD) of YAP betweenβ, γ, and δ isoforms depending on exon 5 and 6 inclusion/exclusion [69].
This in turn affects the transcriptional activity of YAP [70]. Novel neuron-specific YAP isoforms were
recently reported by the Okazawa group [77] and found to be present during a specific type of
slow and progressive neuronal death known as transcriptional repression-induced atypical death
(TRIAD), associated with Huntington’s disease (HD) [77]. These three YAP isoforms (ins13, ins25,
and ins61), referred to as YAP∆Cs, are C-terminal truncated isoforms of YAP and contain additional
mini-exon sequences between exon 5 and exon 6 [77]. During TRIAD these YAP∆Cs functioned in
a dominant-negative manner to suppress neuronal death and were found to be co-localised with
activated p73 in striatal neurons of HD patients and mouse models of HD [77]. YAP∆C isoforms
were also found to attenuate neuronal death in D. melanogaster huntingtin mutants [77]. YAP∆C-ins61
had the strongest anti-TRIAD activity and the therapeutic use of YAP∆C-ins61 in a mouse model
of spinocerebellar ataxia type 1 (SCA1) found that expression of YAP∆C-ins61 in development,
as opposed to during adulthood was required to ameliorate the pathology and symptoms of SCA1
(ataxin-1 knock-in mutant) mice [78]. Specifically, Fujita et al. found that YAP∆C-ins61 functions
as a co-activator of the nuclear receptor retinoid-related orphan receptor alpha (RORα), forming
transcriptional complexes with RORα on cis-elements of target genes to invoke gene expression
necessary for cerebellar development [78]. Since the three YAP∆C isoforms all exhibit a reading frame
shift, resulting in truncation of the C-terminal TAD, it will be interesting to see whether these isoforms
are also present in other tissues, as loss of this C-terminal region would compromise YAP function in
several ways. For example, loss of the YAP PDZ-binding motif associated with the C-terminus would
impair the nuclear shuttling of YAP [79].
Very recently it was reported that YAP nuclear activity is under the control of a splicing
switch. The TEAD4 transcription factor—the major binding partner for YAP in the nucleus—has an
alternatively spliced isoform that produces a truncated version lacking the N-terminal DNA-binding
domain [65]. This truncated TEAD4 isoform (TEAD4-S) is found in both the cytoplasm and nucleus
where it can still bind YAP and acts in a dominant negative manner over full length TEAD4 to repress
YAP activity in both locations. Qi et al. found that production of TEAD4-S is governed by the tumour
suppressor and splicing factor RNA-binding protein 4 (RBM4) by direct binding of RBM4 to TEAD4
pre-mRNA causing skipping of exon 3 [65]. TEAD4-S levels in lung cancer cell lines and patient
samples are reduced, suggesting that TEAD4-S may attenuate YAP signalling to suppress cancer cell
proliferation. In support of this they found that by re-expressing TEAD4-S in two lung cancer cell
lines in vitro they could reduce the proliferation of the cancer cells and reduce expression of the EMT
markers N-cadherin and vimentin. The anti-tumour effects of TEAD4-S were also seen in vivo using
xenografts of cancer cell lines where the truncated isoform slowed tumour growth [65]. Furthermore,
in patient samples from lung and colon cancer that were examined for levels of TEAD4-S, it was found
that those with higher TEAD4-S levels had improved overall survival [65].
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Table 1. Summary of splicing events in the Hippo pathway. Hippo pathway members shown in bold
belong to the core cassette of the Hippo pathway.
Hippo Pathway
Component
Number of Splice
Variants
Potential Consequences of Splice Variant for Hippo Pathway
Signalling Refs.
FAT4 3 (2 protein coding) Not yet known
CD44 39 (27 protein coding) Not yet known
FRMD6 18 (10 protein coding) Not yet known
KIBRA 16 (5 protein coding) Not yet known
NF2/MER 11 (10 protein coding) Not yet known
TAO 6 (3 protein coding) Not yet known
MST1/2 21 (2 protein coding)
C-terminal truncated version of MST1 consists only of kinase domain,
full-length MST1 isoform has C-terminal regulatory region and
homodimerisation SARAH domain. Truncated isoforms of MST1 may
not homodimerise with MST2.
[66]
SAV1 6 (5 protein coding) Forms a complex through its C-terminal SARAH domain with MST1and MST2. Truncated isoforms may not complex. [67]
RASSF 10 (5 protein coding) Forms a complex through its C-terminal SARAH domain with MST1and MST2. Truncated isoforms may not complex. [67]
NDR1/2 2 (2 protein coding) Not yet known
MAP4K 15 (5 protein coding) Not yet known
MOB1 6 (1 protein coding)
Asp63 and Lys104/Lys105 of MOB1 are key residues for binding with
LATS1/2. Splice isoforms lacking these residues may not
bind LATS1/2.
[68]
LATS1 7 (4 protein coding)
AS variants could negatively affect interactions with NF2 or MOB1,
damage the catalytic domain of LATS1 or interfere with activating
phosphorylations from upstream kinases.
[68]
LATS2 2 (1 protein coding)
AS variants could negatively affect interactions with NF2 or MOB1,
damage the catalytic domain of LATS2 or interfere with activating
phosphorylations from upstream kinases.
[68]
YAP 11 (9 protein coding)
β, γ and δ isoforms have altered leucine zippers within TAD domain,
potentially affecting protein interactions. YAP∆C isoforms lack
PDZ-binding motif so may not translocate to nucleus. Both changes
may reduce YAP transcriptional activity.
[69–72,77]
TAZ 24 (8 protein coding) Not yet known
ZO-1/2 12 (8 protein coding) Not yet known
α-cat 44 (27 protein coding) Not yet known
β-cat 15 (10 protein coding) Not yet known
PTPN14 5 (2 protein coding) Not yet known
SCRIB 8 (5 protein coding) Not yet known
MST1: mammalian Ste20-like kinase-1; MOB1: kinase co-activator; LATS1/2: large tumour suppressor kinase 1/2;
AS: alternative splicing; NF2: neurofibromin-2; TAD: transcriptional activation domain; YAP∆C: neuronal-specific
YAP isoforms (ins13, ins25, and ins61).
It is also becoming apparent that downstream target genes of the Hippo pathway can be regulated
by alternatively spliced isoforms of proteins that interact with the Hippo pathway [80]. Receptor
tyrosine-protein kinase erbB-4 (ERBB4) has previously been shown to interact with YAP to induce
expression of the Hippo pathway target gene CTGF [81]. However, Wali et al. determined that certain
ERBB4 splice isoforms (CYT-1 or CYT-2) could affect expression of CTGF, as well as the additional
Hippo target genes CYR61 and SPARC [80]. Specifically, microarrays showed that only the full-length
CYT-2 ERBB4 isoform regulated CTGF and CYR61 expression in basal MCF10A cells (normal human
mammary epithelial cells), whereas both CYT-1 and CYT-2 soluble intracellular domain (ICD) isoforms
upregulated CTGF and CYR61. Both the CYT-1 and CYT-2 ICD forms of ERBB4 also upregulated
SPARC expression, which was associated with increased cell proliferation and invasion in the case
of the ICD CYT-2 isoform. Interestingly, the study found that in the luminal breast cancer T47D cell
line, CTGF and CYR61 were also upregulated by ERBB4 isoforms whereas SPARC was downregulated,
suggesting a cell-type specific role for ERBB4 splice isoforms in regulating Hippo pathway target genes.
In all cases, YAP was predicted to be the upstream transcriptional activator regulating the changes
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in CTGF, CYR61 and SPARC [80]. These data provide interesting evidence of a link between growth
factor receptors and the Hippo pathway and suggest that AS mechanisms extrinsic to the core Hippo
suite of genes can also regulate pathway activity, adding another level of complexity and regulation to
the Hippo pathway.
Recent work suggests that the downstream Hippo pathway components YAP and TEAD can
regulate which splice isoforms of an upstream Hippo component, KIBRA, are expressed in certain
tissues, potentially allowing tissue-specific tailoring of Hippo pathway function [82]. In this study,
mapping analysis identified four novel and differentially used transcription start sites (TSS) within the
KIBRA gene. These TSS were specific to the cell types studied—the human kidney epithelial lines IHKE
and HPCT or the neuroblastoma lines SH-SY5Y and SK-SNSH. By RLM-RACE, two novel TSS were
found in the KIBRA 5′ flanking regions of both IHKE and SH-SY5Y cells, 415bp and 153bp upstream of
the already annotated TSS (designated TSS1c and TSS1b respectively) [82]. The authors then identified
two additional potential TSS in the first intron of KIBRA in the IHKE and HPCT cell lines as well as
kidney biopsies, but not in the neuroblastoma cell lines or neuroblastoma biopsies. These sites were
designated TSS2 and TSS3 and were subsequently found to generate two novel alternative exons with
a length of 328bp and 205bp that were termed exons 2a and 2b, respectively [82]. Guske et al. also
discovered that KIBRA expression is regulated by the constitutively active core promoter P1 and three
alternative promoters (P1b, P2, and P3) in kidney cells [82]. Specifically, they detected two distinct
promoter regions that directed significant transcriptional activity for TSS1b and TSS1c (P1a and P1b)
and found that the intronic promoter regions P2 and P3 drove TSS2 and TSS3. Finally, the study
found that the transcription factor TCF7L2 was involved in regulating KIBRA expression. Previous
ChIP-on chip analysis has shown YAP1 and TEAD1 to be targets of TCF7L2 [83] and Guske et al.
showed that the P1a and P2 promoter regions they identified contained binding sequences for TCF7L2.
Subsequently they observed enhanced transcriptional activity for KIBRA promoter deletion constructs
when co-transfected with full length TCF7L2, YAP1 and TEAD1 in kidney cells. Interestingly, they
also observed synergistic transcriptional activation effects when co-transfecting KIBRA promoter
deletion constructs with TCF7L2, YAP1 and TEAD1. Taken together, these data provide evidence that
KIBRA expression is driven by an alternative promoter system, which is differentially activated by
the transcription factor complex of TCF7L2, YAP1, and TEAD1 and may hint at a possible feedback
regulatory mechanism between downstream and upstream components of the Hippo pathway.
It is also possible that external and environmental factors may be linked to AS that can affect the
Hippo pathway. A recent paper from the Zhang group [84] shows that the toxic metal cadmium, which
can enter the body through contaminated water, air and food, and can readily accumulate in the body
and particularly the ovaries, can affect kit ligand (KITL) pre-mRNA AS of exon 6 changing the ratio of
kitl1/kitl2 mRNA. Treatment of murine ovarian cells with cadmium was shown to affect the expression
of 29 microRNAs (miRNAs) associated with the KITL gene [84]. Gene ontology analysis showed that
the target genes of these 29 miRNAs were enriched in biological processes such as cellular metabolism,
signal transduction, cell cycle and proliferation, differentiation and migration. Interestingly, Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathway analysis showed that some of the target genes
of these 29 miRNAs were enriched in the Hippo pathway, providing new evidence that environmental
factors can affect the Hippo pathway by modulating AS [84].
5. The Hippo Pathway and Disease
Given the range of inputs that can regulate Hippo pathway activity and the vast array of biological
processes that are associated with Hippo signalling, tight control of this pathway is essential for
normal functioning of tissues and homeostatic processes. To highlight the importance of controlling
Hippo signalling, we will briefly outline some examples of disease states where aberrant Hippo
signalling has been found to play a role. Altered YAP/TAZ levels have been implicated in a variety
of cancers including breast, pancreatic, prostate, liver, lung, bladder, gliomas, melanomas, sarcomas,
colorectal, ovarian, gastric and head and neck cancers (reviewed in [1]). In some instances of cancer,
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it has been shown that inactivity of upstream Hippo pathway members (e.g., through mutations in
NF2/MERLIN, LATS1, LATS2 or SAV1) can lead to over-activity of YAP/TAZ, which can lead to tumour
initiation [85–88].
However, mutations in core upstream regulators of the Hippo pathway in cancers where
YAP/TAZ activity is high are surprisingly infrequent, suggesting other mechanisms leading to the
stabilisation of YAP/TAZ may be more important in these contexts [1]. Such mechanisms could
include promoter hypermethylation, mutation and amplification [89]. YAP/TAZ are able to drive
many of the traits associated with cancer cells including irregular cell proliferation [61], increased
cell survival [62,90,91], expansion of the cancer stem cell population driving the tumour [92–95],
and chemoresistance and metastasis by regulating the tumour microenvironment [96]. Interestingly,
in pancreatic cancer it has been shown that YAP/TAZ can compensate for activating mutations in
the classical oncogenic driver, KRAS, suggesting a means for the cancer to bypass oncogenic MAPK
signalling and the associated therapeutic approaches [97], highlighting the need for therapies targeted
at YAP/TAZ for cancer.
Altered Hippo pathway signalling has also been linked to cardiovascular diseases [98,99],
neurodegenerative disorders (e.g., [100]) and ocular diseases. A causal mechanism for arrhythmogenic
right ventricular cardiomyopathy (ARVC) was recently shown to be reduced transcriptional activity
of YAP due to phosphorylation by upstream Hippo components [101]. A pathological hallmark of
ARVC is the replacement of cardiomyocytes by fibro-adipocytes, predominantly in the right ventricle.
Knockdown of LATS1/2 in ARVC model myocyte lines restored adipogenesis to levels observed in
normal myocytes [101]. The Hippo pathway is also implicated in Holt–Oram syndrome, which involves
defects of the heart due to mutations in the transcription factor TBX5 [102]. These mutations prevent
TBX5 binding YAP/TAZ resulting in congenital heart defects [103]. YAP/TAZ have been reported
to regulate gene transcription induced by AβPP, the precursor of amyloid β, which is implicated
in driving Alzheimer’s disease [104]. YAP/TAZ regulate this transcription through interactions
with MINT1 and MINT3. Furthermore, MST1 is a key player in amyotrophic lateral sclerosis (ALS).
MST1 activity is increased in mouse models of ALS and when MST1 is knocked out in these mice
they display increased motor neuron viability with delayed symptom onset accompanied by extended
survival [105]. Increased expression of MOB1 and LATS1 is observed in early retinal degeneration,
which is associated with alterations in photoreceptor proliferation and deregulation of cell cycle
genes [106]. Keratoconus, in which the cornea progressively thins and becomes cone-shaped, has been
linked to changes in collagen synthesis and maturation [107] associated with downregulation of core
Hippo pathway members. Ocular coloboma, the most common eye birth defect, is characterised
by an optic fissure closure defect [108]. Williamson et al. found through exosome sequencing of
affected individuals the presence of two different heterozygous nonsense mutations in YAP1 (c.370C > T
(p. Arg124*) and c. 1066G > T (p. Glu356*)) [108]. The study found an alternative TSS in intron 1 of
YAP1 and concluded that c.370C > mutations occurring in these alternative YAP1 transcripts resulted
in no NMD, suggesting the process of optic fissure may be sensitive to YAP1 dosage [108].
Polycystic kidney disease (PKD) is a serious condition where cysts form throughout the kidneys.
Frequently this is associated with inactivating mutations in PKD1 and PKD2 [109]. The YAP1 target
gene, FJX1, which is required for tubular regeneration in the kidneys following injury, is unchanged in
expression in PKD1 knockout mice [110]. However, unlike in normal kidneys, YAP has been found
to persist in the nucleus following recovery leading to cyst formation [110]. Somewhat surprisingly,
TAZ plays a different role in PKD progression. TAZ complexes with PC2, the product of PKD1, leading
to ubiquitination and degradation of PC2 [109]. Consequently, loss of TAZ leads to accumulation of
PC2 and development of PKD [109,111,112].
Clearly then from the examples above, there is merit in targeting the Hippo pathway
therapeutically for disease amelioration. In the future it will be interesting to elucidate whether
specific AS variants of Hippo pathway members may play a role in disease (Table 2), and it is likely
that as research in this area progresses, any Hippo pathway AS variants found to be responsible for
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disease states will provide new therapeutic targets. Several AS variants of YAP, namely YAP1β, YAP1γ
and YAP1δ have disruptions to the amino acid sequence of the leucine zipper region encoded within
the TAD domain of YAP, that might render it thermodynamically unstable [69]. Since the formation
of leucine zippers is important for the interaction of YAP with other proteins, it is likely that these
YAP isoforms will have problems associating with some of the common cellular binding partners of
YAP [69]. Therefore, it could be speculated that a shift in splicing towards these β, γ and δ variants
would have consequences in terms of signal transduction through YAP within the cell but may also
provide a mechanism for allowing tissue-specific differences in YAP signalling. Deregulation of the
production of these various YAP isoforms in specific tissues at specific times could have negative
outcomes leading to developmental defects or other disease states later in life. Interestingly, in the
corresponding region of TAZ it was found that no AS takes place [69], suggesting that evolutionary
differences between the paralogues may allow for some compensatory effects between YAP and TAZ
should one of these paralogues be affected by defective splicing.
Several pharmacological inhibitors have been designed and tested in an effort to manipulate the
activity of the Hippo pathway. Verteporfin is a small molecule inhibitor that directly binds YAP to
block its interaction with TEAD transcription factors and thusly its transcriptional activity [113,114].
In mice livers overexpressing YAP or with inactivation of NF2/MERLIN, verteporfin was able to
suppress the liver overgrowth observed in non-treated mice and the treated livers presented with
reduced cell proliferation [113]. Dobutamine, which is a G-protein-coupled β-adrenergic receptor
agonist, has been shown to cause dose-dependent cytoplasmic accumulation of GFP-tagged YAP
through phosphorylation at the main serine-127 phosphorylation site of YAP, and hence transcriptional
inactivity [115]. In the case of ivermectin, an antiparasitic drug, which is able to decrease YAP
nuclear accumulation and its transcriptional activity in vitro, the mechanism of action remains
unknown, but this compound also has significant effects on tumour growth in vivo [116]. A host of
compounds targeting cellular cytoskeletal components (e.g., F-actin, Rho, ROCK and non-muscle
myosin), and thus the mechanotransduction pathway that feeds into Hippo signalling have also been
shown to have potentially therapeutically exploitable effects on YAP/TAZ activity. This is pertinent
given the emerging importance of mechanotransduction in the progression of numerous diseases [117].
For example, latrunculin B and cytochalasin D (both targeting F-actin) have been shown to reduce YAP
nuclear localisation via enhanced activity of LATS [91,118,119]. Y27632 (ROCK inhibitor), Blebbistatin
(non-muscle myosin inhibitor) and botulinum toxin C3 (Rho inhibitor) all block nuclear localisation
of YAP/TAZ with a concomitant reduction in target gene transcription [43,91,118], with botulinum
toxin C3 also having been shown to increase phosphorylation of YAP/TAZ and reduce LPA- and
S1P-induced YAP/TAZ dephosphorylation [91].
Undoubtedly the systemic delivery of some of these compounds could have significant off-target
effects given the ubiquitous presence of some of their targets, as well as the widespread nature of
YAP/TAZ and Hippo signalling within the body. Precisely targeted delivery would be required
to ensure such inhibitors did not disrupt normal homeostatic approaches in surrounding healthy
normal tissues. The requirements for a considered approach to therapeutically targeting the Hippo
pathway are supported by examples showing that YAP deletion in the mouse intestine can cause
WNT hypersensitivity leading to enhanced injury-induced stem cell expansion and hyperplasia [120].
As discussed, GPCRs are implicated in Hippo signalling, with Gα12/13, Gαq/11 and to a lesser extent
Gαi/o being demonstrated as potent activators of YAP/TAZ [46], whereas Gαs-coupled GPCR agonists
increase LATS1/2 activity leading to inhibition of YAP/TAZ activity [121]. Interestingly, Gαs-coupled
GPCR signalling pathways can also play a pro-tumorigenic role in some tumour types [122]. Therefore,
compounds targeted against GPCR pathways for therapeutic means could actually increase YAP/TAZ
activity with potentially harmful outcomes.
Therefore, inhibitors/agonists that alter only the disease state-specific aspect of Hippo signalling
or YAP/TAZ activity may be preferable. In particular, therapies that target the most downstream
aspect of Hippo signalling, i.e., YAP-TEAD activity could hold significant therapeutic promise [113].
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One such targeted approach may be to direct therapies at disease-specific or sub-optimal splice variants
of the Hippo pathway, such as the full length TEAD4 isoform seen in lung and colon cancer [65] and
the β, γ, and δ isoforms of YAP with affected TAD domains [69]. Given that the majority of the
core components of the Hippo pathway have splice variants (Figure 2), it seems plausible that a
deregulation in spatio-temporal splicing of these core members could lead to the production of splice
variants with deleterious effects. Such harmful splice isoforms would provide the opportunity to
target disease-causing splice variants without affecting the functioning of normal Hippo signalling,
thus minimising any potential side effects. We will now discuss the prospect of targeting changes in
splicing in the Hippo pathway as a means of treatment for disease.
6. Approaches to Target Alternative Splicing Therapeutically in the Hippo Pathway
Evidence is now emerging for disrupted AS in the Hippo pathway contributing to disease. A study
by Bueno et al. performed a comprehensive genomic analysis of mutations found in malignant pleural
mesothelioma (MPM) tumors [87]. Exome analysis found NF2/MERLIN to be significantly mutated
in MPMs and interestingly NF2/MERLIN was found to be frequently inactivated by recurrent gene
fusions (e.g., with GSTT1) and splicing alterations, namely in-frame deletions predicted to produce a
non-functioning protein [87]. The authors found in-frame deletions of the FERM-central, FERM-PH-like
and FERM-C domains together or the FERM-PH-like domain alone [87]. Such studies highlight the
pertinence of therapeutically targeting disease-specific Hippo pathway splice variants. In support
of such a strategy, the use of cancer-specific splice variants for a variety of genes, as biomarkers and
therapeutic targets is already becoming recognised for various cancers [123]. Approaches could make
use of techniques to bias splicing towards producing normal or disease suppressing variants of the
proteins in question. For example, splicing could be modulated in cases where the inclusion of a
cassette exon is associated with negative outcomes or where aberrant splicing leads to a protein isoform
with a dominant-negative function over the normal variant. Or indeed in cases where the gene/protein
causing disease is overexpressed, such therapeutic approaches could be used to negate levels of
gene expression by introducing premature termination codons (PTCs) into the mRNA produced and
thus NMD.
Splicing-switching oligonucleotides (SSOs) are a class of antisense oligonucleotides that work at
the pre-mRNA level to modify splicing [124] (Figure 3A). Therefore, SSOs can be used to modify the
expression of disease-related genes and their protein products. SSOs are in clinical trials for targeting
neuromuscular disease genes including SMN2 [125–129] validating their use as an approach to treat
previously intractable diseases such as SMA and DMD. Furthermore, SSOs have been used to inactivate
various cancer-associated genes such as HER2, HER4, FLT-1, MDM4, STAT3 or MCL-1 [124,130–135].
In the context of the Hippo pathway, SSOs could be used to affect splicing of the TEAD4 gene
in relevant cancers, causing skipping of exon 3 to produce the truncated tumour suppressor variant
TEAD4-S (Figure 3B), which has been shown to suppress tumour growth in vivo and has been
associated with improved survival in lung and colon cancer patients [65]. Indeed, it might also
be possible to correct the aberrant splicing of NF2/MERLIN reported in MPM tumours [87] that results
in in-frame deletions and a non-functioning protein. Here, SSOs could be targeted to cause retention of
the FERM-central, FERM-PH-like and FERM-C domains that are deleted. In the case of breast cancer,
where certain ERBB4 isoforms activate YAP target genes to promote cell proliferation and invasion,
SSOs may be used to steer splicing towards the production of ERBB4 isoforms that do not result in
YAP transcriptional output. Finally, the functions of the various YAP splice variants are still being
elucidated. YAP1γ has been shown to promote proliferation, colony formation and EMT as well as
protect against apoptosis in MCF10A cells [54,136,137]. YAP1γ in vivo has been shown to cause liver
overgrowth [62]. Conversely, over-expression of the YAP1α variant in the UMSCC-11A squamous cell
carcinoma cell line caused increased cell death [138]. Consequently, targeting YAP isoform production
with SSOs could also have clinical gains. As additional Hippo pathway disease-specific splice variants
are identified, the list of potential therapeutic SSO targets should grow.
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Table 2. Diseases and phenotypes caused by changes in splicing in Hippo pathway components.
Hippo Pathway Component with Changes in
Splicing Associated Disease/Phenotype References
NF2/MERLIN (in-frame deletions predicted to
produce a non-functioning protein) Malignant pleural mesothelioma [87]
YAP (use of alternative TSS in intron 1 of YAP1
accompanied by c.370C > mutation) Ocular coloboma [108]
YAP (YAP1γ—disruptions to the amino acid
sequence of the leucine zipper region encoded
within the TAD domain)
Promotes proliferation, colony formation
and EMT as well as protecting against
apoptosis in MCF10A cells. Causes liver
overgrowth in vivo.
[54,62,136,137]
YAP (YAP1α—shortest YAP1 isoform) Causes increased cell death in UMSCC-11Asquamous cell carcinoma cell line [138]
TEAD4 (TEAD4-S—truncated version lacking the
N-terminal DNA-binding domain)
Tumour suppressive in the context of lung
and colon cancer [65]
EMT: epithelial-to-mesenchymal-transition; TSS: transcription start site.
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Figure 3. Mechanism of action of splice-switching oligonucleotides. (A) By targeting the 3′ acceptor or
5′ donor splice sites, targeted exons can be excluded from the mRNA product; (B) A potential approach
to target exon 3 of TEAD4 to produce TEAD4-S, a tumour-suppressive TEAD4 isoform in the context
of lung and colon cancer. The principles of this approach could be applied to other diseases to target
genes with splicing defects.
As discussed above, there are several inhibitors targeted against the Hippo pathway, mostly
against YAP. To the best of our knowledge, there are currently no reports of inhibitors targeted against
specific splice variants of the YAP protein or other Hippo pathway member protein isoforms. As more
Hippo pathway splice variants are identified, their functions elucidated and associated with disease,
this is likely to change. As the splicing factors and kinases regulating splicing in the Hippo pathway
become more established, it may also be possible to target these pharmacologically, as has been done for
CDC Like Kinase 1 (CLK1) with TG693 in the context of DMD [139]. There is some evidence to suggest
that serine/arginine-rich splicing factor 1 (SRSF1) and YAP can interact [140]. The metastasis-associated
lung adenocarcinoma transcript 1 (Malat1) is over-expressed in several disease states and YAP was
found to upregulate Malat1 in liver cancer, whereas SRSF1 was found to have an opposing effect [140].
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SRSF1 was found to inhibit YAP activity by blocking its binding with TCF/β-catenin on the Malat1
promoter [140]. YAP over-expression could inhibit nuclear localisation of both SRSF1 and YAP due to
their binding with angiomotin, mitigating the inhibitory role of SRSF1 on Malat1 expression resulting
in enhanced transwell migration of hepatocarcinoma cell lines as well as enhanced tumour growth of
hepatocarcinoma cell lines in xenograft models [140]. Whether this interaction between SRSF1 and
YAP remains under normal physiological conditions remains to be seen, but the authors speculate that
disrupting the interaction between SRSF1 and YAP may be a viable therapeutic target to modulate the
Hippo pathway in the context of liver cancer [140].
7. Conclusions
AS is a very important regulator of multicellular eukaryotic gene function, the deregulation of
which contributes to many disease states, including cancer. Likewise, the Hippo pathway, a master
regulator of organ size and the associated biological processes is also highly implicated in disease.
Given the evolutionary and biological significance of this signalling pathway, it is unsurprising that
AS is emerging as a means to offer both an extra layer of regulation of this pathway as well as a means
for the pathway to have diverse functions in different tissues. As our knowledge of the role of AS in
the Hippo pathway expands, we should be able to identify valuable new therapeutic targets specific to
disease states.
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